AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25887461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients' perceptions
Number of subjects: 84
Study 25887461 — intervention group
Group type: EXPERIMENTAL
Intervention: ReDO™ group
Number of subjects: 84
Study 25887461 — intervention group
Group type: COMPARATOR
Intervention: CAU group
Number of subjects: 84
Study 25887576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 2
Study 25887576 — intervention group
Group type: COMPARATOR
Intervention: Standard care sedation (propofol or midazolam)
Number of subjects: 2
Study 25887603 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional methods combined with PCR
Number of subjects: 267
Study 25887603 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 267
Study 25887603 — intervention group
Group type: EXPERIMENTAL
Intervention: OP swab for S. pneumoniae qPCR
Number of subjects: 267
Study 25887603 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology
Number of subjects: 267
Study 25887777 — intervention group
Group type: EXPERIMENTAL
Intervention: AFM13 at doses of 0.01 to 7 mg/kg body weight
Number of subjects: 28
Study 25887777 — intervention group
Group type: EXPERIMENTAL
Intervention: AFM13 at doses of ≥1.5 mg/kg
Number of subjects: 28
Study 25887777 — intervention group
Group type: EXPERIMENTAL
Intervention: AFM13 treatment
Number of subjects: 28
Study 25888272 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab 8 mg/kg on days 1 and 15 and paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 6
Study 25888299 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 25
Study 25888397 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal tubular acidosis (RTA) in patients with hyperchloremic acidosis
Number of subjects: 100
Study 25888397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperchloremic acidosis
Number of subjects: 100
Study 25888397 — intervention group
Group type: EXPERIMENTAL
Intervention: Other acid-base disturbances
Number of subjects: 100
Study 25888403 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop fluid administration system
Number of subjects: 40
Study 25888403 — intervention group
Group type: COMPARATOR
Intervention: Manual management (Control)
Number of subjects: 40
Study 25888646 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (3 doses) followed by PPSV23 (1 dose)
Number of subjects: 301
Study 25888856 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples' Health CoOp intervention targeting men who use alcohol and other drugs and engage in unprotected sex, and their main female sex partners. The intervention includes components addressing substance use, sex risk, HIV and other STIs, gender roles, gender-based violence, communication skills, and goal-setting activities.
Number of subjects: 0
Study 25888961 — intervention group
Group type: COMPARATOR
Intervention: Entropy in the central retinal artery (CRA)
Number of subjects: 42
Study 25888961 — intervention group
Group type: COMPARATOR
Intervention: Entropy in the ophthalmic artery
Number of subjects: 42
Study 25888961 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive index in the CRA
Number of subjects: 42
Study 25888961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatility index in the CRA
Number of subjects: 42
Study 25889044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat 20 mg
Number of subjects: 6
Study 25889044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat 40 mg
Number of subjects: 6
Study 25889044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat
Number of subjects: 6
Study 25889305 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (3 g/day for 6 weeks)
Number of subjects: 208
Study 25889305 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 208
Study 25889498 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 610660
Study 25889498 — intervention group
Group type: COMPARATOR
Intervention: Non-DPP-4 inhibitor OAD
Number of subjects: 610660
Study 25889594 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet breathing
Number of subjects: 10
Study 25889594 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic hyperventilation
Number of subjects: 10
Study 25889594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnic hyperventilation
Number of subjects: 10
Study 25890251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal use of bone marrow-derived stem cells
Number of subjects: 20
Study 25890322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional screening by nutritional specialists
Number of subjects: 140
Study 25890322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low lean body mass
Number of subjects: 140
Study 25890322 — intervention group
Group type: EXPERIMENTAL
Intervention: Few (≤3) active co-morbidities
Number of subjects: 140
Study 25890322 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with nutritional supplements
Number of subjects: 140
Study 25890322 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of malnourished patients as assessed by nutritional specialists
Number of subjects: 140
Study 25890322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low weight loss
Number of subjects: 140
Study 25890322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin concentration
Number of subjects: 140
Study 25890582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact fibrous cap (IFC)
Number of subjects: 140
Study 25890582 — intervention group
Group type: COMPARATOR
Intervention: Ruptured fibrous cap (RFC)
Number of subjects: 140
Study 25890604 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week weight loss intervention including healthy diet information, exercise increase, and telephone-based coaching using SMART goals
Number of subjects: 13
Study 25890604 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week weight loss intervention
Number of subjects: 13
Study 25890676 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group
Number of subjects: 58
Study 25890676 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain group
Number of subjects: 58
Study 25890676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 25890798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 517
Study 25890798 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% or greater decline in forced vital capacity (FVC)
Number of subjects: 517
Study 25890798 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory events leading to hospital admission
Number of subjects: 517
Study 25891040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet foods
Number of subjects: 198
Study 25891040 — intervention group
Group type: EXPERIMENTAL
Intervention: Savory foods
Number of subjects: 198
Study 25891040 — intervention group
Group type: EXPERIMENTAL
Intervention: Salty foods
Number of subjects: 198
Study 25891040 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to eat (factor analysis)
Number of subjects: 198
Study 25891040 — intervention group
Group type: EXPERIMENTAL
Intervention: Liking ratings
Number of subjects: 198
Study 25891174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg or 10 mg per kg every 3 weeks or 10 mg per kg every 2 weeks)
Number of subjects: 495
Study 25891346 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 131
Study 25891993 — intervention group
Group type: EXPERIMENTAL
Intervention: C-FLAG (fludarabine and cytarabine as a 24-hr continuous infusion without idarubicin)
Number of subjects: 33
Study 25891993 — intervention group
Group type: COMPARATOR
Intervention: CI-FLAG2 (C-FLAG with idarubicin)
Number of subjects: 33
Study 25891993 — intervention group
Group type: EXPERIMENTAL
Intervention: C-FLAG
Number of subjects: 33
Study 25892292 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium (se Mg) deficiency group
Number of subjects: 143
Study 25892292 — intervention group
Group type: COMPARATOR
Intervention: Serum vitamin D (se vitD) and serum calcium (se Ca)
Number of subjects: 143
Study 25892292 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium (se Mg)
Number of subjects: 143
Study 25893247 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin testing capability in hospitals
Number of subjects: 14370
Study 25893247 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of troponin assay
Number of subjects: 14370
Study 25893247 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker testing capability
Number of subjects: 14370
Study 25893247 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin testing
Number of subjects: 14370
Study 25893247 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker measurement
Number of subjects: 14370
Study 25893603 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal microarrays to detect genomic imbalances in children with CKD
Number of subjects: 419
Study 25893603 — intervention group
Group type: COMPARATOR
Intervention: Chromosomal microarrays
Number of subjects: 419
Study 25894585 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum copeptin levels in children with febrile seizures
Number of subjects: 161
Study 25894585 — intervention group
Group type: COMPARATOR
Intervention: Serum copeptin levels in febrile controls
Number of subjects: 161
Study 25894585 — intervention group
Group type: COMPARATOR
Intervention: Serum copeptin levels in children with epileptic seizures
Number of subjects: 161
Study 25894585 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of copeptin
Number of subjects: 161
Study 25894585 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of copeptin at different time intervals
Number of subjects: 161
Study 25894712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mullen Scales of Early Learning (MSEL)
Number of subjects: 399
Study 25895428 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg and elbasvir 50 mg QD with weight-based ribavirin BID for 12 weeks
Number of subjects: 79
Study 25895616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 30mg oral daily (od)
Number of subjects: 74
Study 25896080 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive sport
Number of subjects: 108
Study 25896080 — intervention group
Group type: COMPARATOR
Intervention: Recreational sport
Number of subjects: 108
Study 25896390 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Number of subjects: 9
Study 25896421 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-DropMount technique following CellSearch isolation
Number of subjects: 0
Study 25896421 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-DropMount technique
Number of subjects: 0
Study 25896707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 32
Study 25896785 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused rehabilitation
Number of subjects: 413
Study 25896785 — intervention group
Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 413
Study 25896788 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 hours MPHD with a dialysate volume of 50% of estimated body water volume
Number of subjects: 9
Study 25896788 — intervention group
Group type: COMPARATOR
Intervention: 4 hours SHD using a dialysate flow of 500 mL/min
Number of subjects: 9
Study 25896788 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficiency calculated as solute removal/litre of dialysate used
Number of subjects: 9
Study 25896788 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 times/week 8 hours MPHD
Number of subjects: 9
Study 25897014 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression by immune cells
Number of subjects: 3916
Study 25897014 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression by tumour cells
Number of subjects: 3916
Study 25897014 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression in basal-like tumours (IntClust 10)
Number of subjects: 3916
Study 25897014 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression in basal-like tumours (surrogate IHC-based classifier)
Number of subjects: 3916
Study 25897014 — intervention group
Group type: EXPERIMENTAL
Intervention: CD274 (PD-L1) amplification
Number of subjects: 3916
Study 25897014 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PD-L1 expression with T cell infiltration
Number of subjects: 3916
Study 25897014 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression and disease-specific survival in ER-negative disease
Number of subjects: 3916
Study 25897792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide (5 mg to 60 mg a day, maximum)
Number of subjects: 29
Study 25898341 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based Separated Family Treatment (ASFT)
Number of subjects: 0
Study 25898394 — intervention group
Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire (IPAQ)
Number of subjects: 211
Study 25898394 — intervention group
Group type: COMPARATOR
Intervention: SenseWear Armband (SWA)
Number of subjects: 211
Study 25898693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatophagoides mix (300, 600, 3000, 6000, and 15000 SQ+) administered at weekly intervals with 1 maintenance injection (15000 SQ+) 2 weeks after the last updosing injection.
Number of subjects: 102
Study 25899176 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol combination (BFC)
Number of subjects: 3697
Study 25899176 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol combination (FSC)
Number of subjects: 3697
Study 25899176 — intervention group
Group type: EXPERIMENTAL
Intervention: BFC
Number of subjects: 3697
Study 25899176 — intervention group
Group type: COMPARATOR
Intervention: FSC
Number of subjects: 3697
Study 25899239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabry disease (FD) patients with MRI findings
Number of subjects: 3203
Study 25899239 — intervention group
Group type: COMPARATOR
Intervention: Non-FD patients with MRI findings
Number of subjects: 3203
Study 25899478 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 71
Study 25899782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine (escalating doses of fludarabine: 15, 45, and 75 mg/m(2))
Number of subjects: 12
Study 25899782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine
Number of subjects: 12
Study 25900065 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab 1600 mg
Number of subjects: 55
Study 25900065 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (all doses)
Number of subjects: 55
Study 25900065 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 55
Study 25900065 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab 500 mg/m²
Number of subjects: 55
Study 25900182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (10 mg/kg i.v.), Everolimus (10 mg p.o. daily), Octreotide LAR (20 mg i.m. every 21 days)
Number of subjects: 19
Study 25900187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective data recording
Number of subjects: 573
Study 25900275 — intervention group
Group type: EXPERIMENTAL
Intervention: APO-E4 carriers
Number of subjects: 41
Study 25900275 — intervention group
Group type: COMPARATOR
Intervention: Noncarriers
Number of subjects: 41
Study 25900467 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitation group (defined by SAS score of 5-7 or RASS score of +2 to +4)
Number of subjects: 0
Study 25900467 — intervention group
Group type: COMPARATOR
Intervention: Non-agitation group (defined by SAS score below 5 or RASS score below +2)
Number of subjects: 0
Study 25900467 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up for 72 hours
Number of subjects: 0
Study 25900467 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of sedatives and analgesics
Number of subjects: 0
Study 25900904 — intervention group
Group type: EXPERIMENTAL
Intervention: RelAte intervention (shared mealtimes with a trained peer volunteer once weekly for 8 weeks)
Number of subjects: 100
Study 25900904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 100
Study 25901047 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 747
Study 25901047 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 747
Study 25901047 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BDI-II score
Number of subjects: 747
Study 25901095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam given 30 min before a clamp during euglycemia
Number of subjects: 31
Study 25901095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam given 30 min before a clamp during hypoglycemia
Number of subjects: 31
Study 25901095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam during euglycemia
Number of subjects: 31
Study 25901095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alprazolam)
Number of subjects: 31
Study 25901286 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS-003 in combination with sunitinib
Number of subjects: 21
Study 25901286 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 21
Study 25901286 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS-003
Number of subjects: 21
Study 25901550 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-sustaining treatments (mechanical ventilation, vasopressors, renal replacement therapy)
Number of subjects: 1671
Study 25901550 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stay
Number of subjects: 1671
Study 25901550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1671
Study 25901550 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from ICU admission to death
Number of subjects: 1671
Study 25901550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation, vasopressors, or dialysis
Number of subjects: 1671
Study 25901550 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty or advance directives
Number of subjects: 1671
Study 25902042 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous melanocyte transplantation on amniotic membrane
Number of subjects: 0
Study 25902042 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25902322 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (used in 99% of cases) with neostigmine for reversal (73.9% at TE, 72.0% at PACU)
Number of subjects: 302
Study 25902322 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (used for reversal of NMB)
Number of subjects: 302
Study 25902709 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis from the APPLE trial assessing associations between AVN and demographics, SLE disease activity, and vitamin D deficiency.
Number of subjects: 0
Study 25902826 — intervention group
Group type: COMPARATOR
Intervention: Snorers (AHI < 5)
Number of subjects: 405
Study 25902826 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe SDB cases (AHI > 30)
Number of subjects: 405
Study 25902826 — intervention group
Group type: EXPERIMENTAL
Intervention: AHI and hypoxemia
Number of subjects: 405
Study 25902826 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index and male gender
Number of subjects: 405
Study 25902842 — intervention group
Group type: EXPERIMENTAL
Intervention: idursulfase 0.5 mg/kg weekly for one year
Number of subjects: 28
Study 25902842 — intervention group
Group type: EXPERIMENTAL
Intervention: idursulfase
Number of subjects: 28
Study 25902855 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE)
Number of subjects: 0
Study 25902855 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25902926 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium (Cresemba®)
Number of subjects: 0
Study 25903311 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 25
Study 25903529 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study 25903659 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 510
Study 25903963 — intervention group
Group type: EXPERIMENTAL
Intervention: PEI regimen (Cisplatin 20 mg/m2, Etoposide 75 mg/m2, Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks)
Number of subjects: 46
Study 25904000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobil-O-Graph (MogPWV)
Number of subjects: 143
Study 25904000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 143
Study 25904000 — intervention group
Group type: EXPERIMENTAL
Intervention: MogPWV
Number of subjects: 143
Study 25904000 — intervention group
Group type: COMPARATOR
Intervention: Control group (eGFR > 30 ml/min)
Number of subjects: 143
Study 25904368 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of Multidrug-Resistant Enterobacteriaceae (MRE)
Number of subjects: 574
Study 25904368 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of carbapenemase-producing Enterobacteriaceae
Number of subjects: 574
Study 25904368 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE acquisition by region
Number of subjects: 574
Study 25904368 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE carriage duration
Number of subjects: 574
Study 25904368 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with MRE acquisition
Number of subjects: 574
Study 25904368 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage duration based on region
Number of subjects: 574
Study 25904601 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HFCS (n = 18)
Number of subjects: 85
Study 25904601 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5% HFCS (n = 16)
Number of subjects: 85
Study 25904601 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% HFCS (n = 28)
Number of subjects: 85
Study 25904601 — intervention group
Group type: COMPARATOR
Intervention: 0% HFCS (aspartame sweetened, n = 23)
Number of subjects: 85
Study 25904635 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs2268361-T in FSHR
Number of subjects: 485